Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Daniil Gataulin from Chardan Capital initiated Ocular Therapeutix, Inc. (NASDAQ:OCUL) with a Buy rating and a $21 price target. The analyst highlighted the company’s Axpaxli program, which is the company’s lead program and is being gradually launched over several months. Axpaxli aims to reduce the treatment burden for patients who need frequent anti-VEGF injections. These injection ...